Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Autor: Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, Peter C. Arden, Annie Baker, James C. Bennett, Catherine Bird, Renske E. Blom, Christine Brennan, Donna Brusch, Lisa Burke, Kete Campbell-Coker, Robin Carhart-Harris, Joseph Cattell, Aster Daniel, Charles DeBattista, Boadie W. Dunlop, Katherine Eisen, David Feifel, MacKenzie Forbes, Hannah M. Haumann, David J. Hellerstein, Astrid I. Hoppe, Muhammad I. Husain, Luke A. Jelen, Jeanine Kamphuis, Julie Kawasaki, John R. Kelly, Richard E. Key, Ronit Kishon, Stephanie Knatz Peck, Gemma Knight, Martijn H.B. Koolen, Melanie Lean, Rasmus W. Licht, Jessica L. Maples-Keller, Jan Mars, Lindsey Marwood, Martin C. McElhiney, Tammy L. Miller, Arvin Mirow, Sunil Mistry, Tanja Mletzko-Crowe, Liam N. Modlin, René E. Nielsen, Elizabeth M. Nielson, Sjoerd R. Offerhaus, Veronica O’Keane, Tomáš Páleníček, David Printz, Marleen C. Rademaker, Aumer van Reemst, Frederick Reinholdt, Dimitris Repantis, James Rucker, Samuel Rudow, Simon Ruffell, A. John Rush, Robert A. Schoevers, Mathieu Seynaeve, Samantha Shao, Jair C. Soares, Metten Somers, Susan C. Stansfield, Diane Sterling, Aaron Strockis, Joyce Tsai, Lucy Visser, Mourad Wahba, Samuel Williams, Allan H. Young, Paula Ywema, Sidney Zisook, Ekaterina Malievskaia

Publikováno v: Goodwin, G M, Aaronson, S T, Alvarez, O, Arden, P C, Baker, A, Bennett, J C, Bird, C, Blom, R E, Brennan, C, Brusch, D, Burke, L, Campbell-Coker, K, Carhart-Harris, R, Cattell, J, Daniel, A, DeBattista, C, Dunlop, B W, Eisen, K, Feifel, D, Forbes, M, Haumann, H M, Hellerstein, D J, Hoppe, A I, Husain, M I, Jelen, L A, Kamphuis, J, Kawasaki, J, Kelly, J R, Key, R E, Kishon, R, Knatz Peck, S, Knight, G, Koolen, M H B, Lean, M, Licht, R W, Maples-Keller, J L, Mars, J, Marwood, L, McElhiney, M C, Miller, T L, Mirow, A, Mistry, S, Mletzko-Crowe, T, Modlin, L N, Nielsen, R E, Nielson, E M, Offerhaus, S R, O’Keane, V, Páleníček, T, Printz, D, Rademaker, M C, van Reemst, A, Reinholdt, F, Repantis, D, Rucker, J, Rudow, S, Ruffell, S, Rush, A J, Schoevers, R A, Seynaeve, M, Shao, S, Soares, J C, Somers, M, Stansfield, S C, Sterling, D, Strockis, A, Tsai, J, Visser, L, Wahba, M, Williams, S, Young, A H, Ywema, P, Zisook, S & Malievskaia, E 2022, ' Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression ', New England Journal of Medicine, vol. 387, no. 18, pp. 1637-1648 . https://doi.org/10.1056/NEJMoa2206443
The New England journal of medicine, 387(18), 1637-1648. MASSACHUSETTS MEDICAL SOC
Goodwin, G M, Aaronson, S T, Alvarez, O, Arden, P C, Baker, A, Bennett, J C, Bird, C, Blom, R E, Brennan, C, Brusch, D, Burke, L, Campbell-Coker, K, Carhart-Harris, R, Cattell, J, Daniel, A, DeBattista, C, Dunlop, B W, Eisen, K, Feifel, D, Forbes, M, Haumann, H M, Hellerstein, D J, Hoppe, A I, Husain, M I, Jelen, L A, Kamphuis, J, Kawasaki, J, Kelly, J R, Key, R E, Kishon, R, Knatz Peck, S, Knight, G, Koolen, M H B, Lean, M, Licht, R W, Maples-Keller, J L, Mars, J, Marwood, L, McElhiney, M C, Miller, T L, Mirow, A, Mistry, S, Mletzko-Crowe, T, Modlin, L N, Nielsen, R E, Nielson, E M, Offerhaus, S R, O'Keane, V, Páleníček, T, Printz, D, Rademaker, M C, van Reemst, A, Reinholdt, F, Repantis, D, Rucker, J, Rudow, S, Ruffell, S, Rush, A J, Schoevers, R A, Seynaeve, M, Shao, S, Soares, J C, Somers, M, Stansfield, S C, Sterling, D, Strockis, A, Tsai, J, Visser, L, Wahba, M, Williams, S, Young, A H, Ywema, P, Zisook, S & Malievskaia, E 2022, ' Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. ', The New England Journal of Medicine, vol. 387, no. 18, pp. 1637-1648 . https://doi.org/10.1056/NEJMoa2206443

BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression.METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b8742fc702d2c23f77f5222cb3a4d0
https://doi.org/10.1056/nejmoa2206443

A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT: a three-arm parallel blinded randomised controlled single-centre trial

Autor: Peter Leander, Georgios Stathis, Lucia Casal-Dujat, Karolina Boman, Ingvar Adnerhill, Jan Marsal, Olof Böök, Thomas Fork

Publikováno v: European Radiology Experimental, Vol 6, Iss 1, Pp 1-9 (2022)

Abstract Background A negative oral contrast agent (OCA) has been long sought for, to better delineate the bowel and visualise surrounding structures. Lumentin® 44 (L44) is a new OCA formulated to fill the entire small bowel. The aim of this study w

Externí odkaz: https://doaj.org/article/0ba49b0b0a6d40aabbe7e8ae9ff20648

Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis

Autor: Jonas Sagard, Tor Olofsson, Elisabeth Mogard, Jan Marsal, Kristofer Andréasson, Mats Geijer, Lars Erik Kristensen, Elisabet Lindqvist, Johan K. Wallman

Publikováno v: Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-14 (2022)

Abstract Background Based on clinical and genetic associations, axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) are suspected to have a linked pathogenesis. Gut dysbiosis, intrinsic to IBD, has also been observed in axSpA. It is,

Externí odkaz: https://doaj.org/article/6af765f9144b4ab29b51e99f3646e856

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Autor: Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian

Publikováno v: Frontiers in Medicine, Vol 9 (2022)

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step-up” and “top-down” approaches, and has become a cornerstone of IB

Externí odkaz: https://doaj.org/article/18c3d1619cc44446ab85ae39a2e8f065

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

Autor: Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Jenny Gunnarsson, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, David Öberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 14 (2021)

Background: Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD). Methods: This study was a prospective, obser

Externí odkaz: https://doaj.org/article/546171ef141e431a8b1359defa38ac04